Michel Dupon

Author PubWeight™ 37.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007 3.38
2 Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011 2.28
3 Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008 2.01
4 Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007 1.55
5 Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002 1.54
6 Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002 1.50
7 Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterol Clin Biol 2006 1.42
8 Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002 1.17
9 Introduction of SARS in France, March-April, 2003. Emerg Infect Dis 2004 1.10
10 HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010 1.08
11 Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis 2004 1.03
12 Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005 1.03
13 Association between psoas abscess and prosthetic hip infection: a case-control study. Acta Orthop 2009 1.01
14 Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2002 1.00
15 Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009 1.00
16 Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis 2012 0.96
17 Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS 2005 0.94
18 Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS One 2010 0.93
19 Infectious Diseases Society of America guidelines for the diagnosis and management of prosthetic joint infection: what is the correct duration of antibiotic treatment? Clin Infect Dis 2013 0.91
20 Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2007 0.90
21 Candida prosthetic infections: case series and literature review. Scand J Infect Dis 2010 0.89
22 Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. Gastroenterol Clin Biol 2007 0.87
23 Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol 2003 0.86
24 Variable-number tandem-repeat markers for typing Mycobacterium intracellulare strains isolated in humans. BMC Microbiol 2010 0.85
25 Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort. Curr HIV Res 2010 0.83
26 Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2001 0.83
27 Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2013 0.80
28 Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. Clin Infect Dis 2005 0.80
29 Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. J Acquir Immune Defic Syndr 2009 0.80
30 CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. J Infect Dis 2002 0.78
31 Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf 2007 0.77
32 HIV and HCV co-infection: situation at six French university hospitals in the year 2000. J Med Virol 2003 0.76
33 Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus. J Clin Microbiol 2006 0.76
34 Emergence of tularemia in the Landes area. Int J Infect Dis 2012 0.75
35 Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management. Nephron 2017 0.75
36 Serum ST2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aquitaine Cohort, France. AIDS 2017 0.75
37 Prevalence of Mycoplasma genitalium among HIV-infected women, Agence Nationale de Recherches sur le SIDA et les hépatites virales CO3 Aquitaine Cohort, France. Sex Transm Dis 2013 0.75
38 [Tuberculosis]. Rev Prat 2009 0.75
39 Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. J Clin Virol 2006 0.75
40 Prognostic factors of calcaneal osteomyelitis. Scand J Infect Dis 2014 0.75
41 Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. AIDS 2017 0.75
42 Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003 0.75
43 Molecular characterization of non-B HIV type 1 isolates from patients of a department of infectious diseases, University Hospital of Bordeaux, France, 1989-2009. AIDS Res Hum Retroviruses 2012 0.75
44 HIV-1 transmission during scintigraphy. Lancet 2003 0.75
45 Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort. J Acquir Immune Defic Syndr 2008 0.75
46 Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. J Acquir Immune Defic Syndr 2003 0.75
47 Characteristics of prosthetic joint infections leading to bacteremia: a case-control study. Scand J Infect Dis 2013 0.75
48 Hyperprocalcitonemia due to mushroom poisoning. Clin Infect Dis 2011 0.75
49 [Fascioliasis: a 23-year retrospective study]. Presse Med 2007 0.75
50 An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients. J Clin Virol 2006 0.75
51 Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1. Antivir Ther 2002 0.75
52 CMV plasma DNAemia and risk of cancer among HIV-infected patients: a case-control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002-2007. J Clin Virol 2010 0.75